BCM
LPCN icon

Bridgeway Capital Management’s Lipocine LPCN Stock Holding History

Bridgeway Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-24,665
Closed -$123K – 1401
2023
Q2 		$123K Hold
24,665
– – ﹤0.01% 1225
2023
Q1 		$133K Sell
24,665
-374
-1% -$2.89K ﹤0.01% 1178
2022
Q4 		$163K Hold
25,039
– – ﹤0.01% 1135
2022
Q3 		$192K Hold
25,039
– – 0.01% 1149
2022
Q2 		$341K Buy
25,039
+14,635
+141% +$228K 0.01% 967
2022
Q1 		$242K Buy
+10,404
New +$218K ﹤0.01% 1135

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bridgeway Capital Management's LPCN Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Lipocine (LPCN) in Q3 2023, closing a stake of 24,665 shares — an estimated $123K sold.

Bridgeway Capital Management first reported a position in LPCN in Q1 2022 and held it in 6 quarters. The position peaked at $341K in Q2 2022. 21 funds tracked by Wall St. Rank hold LPCN as of Q3 2023.

  • Bridgeway Capital Management reported no remaining Lipocine position as of Q3 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 24,665 Lipocine shares in Q3 2023, an estimated $123K.
  • Bridgeway Capital Management first reported a position in Lipocine in Q1 2022 and held it in 6 quarters.
  • Bridgeway Capital Management's Lipocine position peaked at $341K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Lipocine as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.